3-(3-(2-chlorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-N-cyclopropyl-5-fluoro-4-methylbenzamide | 1019916-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(3-(2-chlorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-N-cyclopropyl-5-fluoro-4-methylbenzamide
• 英文别名: 3-[3-(2-chlorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide
• CAS: 1019916-93-8
• 化学式: C₂₃H₁₈ClFN₄O
• 分子量: 420.874
• InChiKey: KJNMNIOIMLFSOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-hydrazinyl-4-iodopyridine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 叠氮基三甲基硅烷 、 1-羟基苯并三唑 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 偶氮二甲酸二乙酯 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 6.0h， 生成 3-(3-(2-chlorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-N-cyclopropyl-5-fluoro-4-methylbenzamide
  参考文献：
  名称：

  Novel triazolopyridylbenzamides as potent and selective p38α inhibitors

  摘要：

  A new class of p38 alpha inhibitors based on a biaryl-triazolopyridine scaffold was investigated. X-ray crystallographic data of the initial lead compound cocrystallised with p38 alpha was crucial in order to uncover a unique binding mode of the inhibitor to the hinge region via a pair of water molecules. Synthesis and SAR was directed towards the improvement of binding affinity, as well as ADME properties for this new class of p38 alpha inhibitors and ultimately afforded compounds showing good in vivo efficacy. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.099

文献信息

• Imidazo- and triazolo-pyridine compounds and methods of use thereof
  申请人：Zhang Dawei

  公开号：US20080161303A1

  公开（公告）日：2008-07-03

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, B, R 1 , R 2 , R 3 and R 4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新的化合物，用于预防和治疗与蛋白激酶介导的疾病有关的疾病，包括炎症和相关病症。这些化合物具有通用的I式，其中A、B、R1、R2、R3和R4在此处被定义。该发明还涵盖包括I式中的一个或多个化合物的制药组合物，以及用于治疗P38地图激酶介导的疾病，包括类风湿性关节炎、牛皮癣和其他炎症性疾病的化合物和组合物的用途，以及用于制备I式化合物的中间体和工艺。
• 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES
  申请人：Vidal Juan Bernat

  公开号：US20100120731A1

  公开（公告）日：2010-05-13

  New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.

  本文披露了具有一般式(I)的p38丝裂原活化蛋白激酶的新抑制剂，以及它们的制备过程，包括它们的药物组成物和在治疗中的应用。
• IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF
  申请人：Amgen Inc.,

  公开号：EP2086973A2

  公开（公告）日：2009-08-12
• NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES
  申请人：Almirall, S.A.

  公开号：EP2118100A1

  公开（公告）日：2009-11-18
• US7700593B2
  申请人：——

  公开号：US7700593B2

  公开（公告）日：2010-04-20